Yesterday, PhRMA filed comments on negotiating objectives for the modernization of the North American Free Trade Agreement (NAFTA). The Administration’s review of our trading relationship with Mexico and Canada serves as a critical point in time for the U.S. to seek to resolve a number of outstanding issues stemming from weak enforcement of existing intellectual property (IP) commitments, and price-setting measures being considered by our trading partners, under NAFTA and other international obligations.
U.S. biopharmaceutical manufacturers rely on predictable and transparent IP policies, which are fundamental for robust innovation and continued economic growth and job creation. NAFTA set a strong baseline for IP protection, and has helped make Canada and Mexico top trading partners for U.S. biopharmaceuticals. However, recent actions by Canada and Mexico demonstrate inadequate enforcement of existing obligations; which is why upcoming negotiations require renewed attention to protect U.S. innovation.
In Canada, the judiciary has recently created a new and heightened standard for determining patent “utility,” which has resulted in the invalidation of 25 biopharmaceutical patents since 2005. Canada remains the only country in the world that interprets patent utility in this manner, breaking the letter and spirit of its NAFTA obligations by undermining patent protection and removing an incentive that is critical to driving and sustaining biopharmaceutical innovation.
Additionally, in both Mexico and Canada, the protection of confidential business information (CBI) and regulatory data protection (RDP) remain uncertain. Despite the fact that NAFTA and other agreements require CBI—including biopharmaceutical clinical trial and other data—to be protected against disclosure, except where “necessary to protect the public,” Canada has lowered this objective threshold—flying in the face on their international obligations. And, while Mexico has taken initial steps to implement RDP provisions by issuing guidelines to key federal agencies, the country has failed to fully implement their RDP obligations as the guidelines can be rescinded at any time because they have not been reflected in any national regulations or legislation.
Other policies, in addition to weak IP enforcement, have the potential to threaten innovation and access to breakthrough biopharmaceuticals. In Canada, for example, both the Ministry of Health and the Patented Medicines Pricing Review Board (PMPRB) are exploring an expansion of Canada’s price setting mandate that would, for example, eliminate the U.S. as a reference country and instead adopt pricing setting measures from other countries. Changes to the PMPRB mandate could affect how Canadian pharmaceutical prices are established and benchmarked against pricing in other markets, which could – in turn – potentially hamper patient access to medicines.
As part of its effort to modernize NAFTA, the U.S. should seek to ensure stronger enforcement of patentability standards and the provisions that protect the IP of U.S. innovators, as well as address potentially negative price-setting measures. Maintaining strong policies will help promote the discovery of new medicines and support our economy and workforce.
Mark Grayson
Mark Grayson is a former deputy vice president of public affairs at PhRMA focusing on intellectual property, trade and international issues.
Mark Grayson
Tariffs on medicines would harm American competitiveness, industry and patients
Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation
USTR remembers—three years later—that it announced a trade initiative with Europe
PhRMA submission calls for USTR to correct course on trade policy, enforcement
No Region Left Behind: USTR expands its unambitious trade agenda to the western hemisphere
World Trade Week 2024: Time for a more ambitious U.S. trade agenda
Why won’t USTR strengthen medical supply chains with America’s allies?
PhRMA 2024 Special 301 submission: USTR needs to support American innovation, global access to medicines
Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation
PhRMA submission: USTR needs more ambition to combat unfair trade barriers
The Biden Administration has failed to advance an inclusive, worker-centered trade agenda
Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth
U.S. biopharmaceutical exports support jobs, innovation
Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?
Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade
PhRMA submission to USTR calls for urgent defense of American innovation abroad
Partnerships are driving global COVID-19 treatment access
The dangers of expanding the TRIPS waiver
Biden Administration details inadequate protection of American intellectual property and foreign barriers to innovation abroad
PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
Strengthening the WTOs global trade and health agenda
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
American leadership on innovation policy is essential to global health progress
Preserving U.S. innovation worldwide is more important than ever
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
The continued imperative to protect U.S. innovation worldwide
Trump administration must defend and protect U.S. innovation
PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation
Setting the record straight on international reference pricing
World Trade Month: How we can expand world-class pro-innovation standards
Special 301 submission calls for a level playing field for American innovators
Fact Check: Biologics, regulatory data protection and the United States-Mexico-Canada Agreement
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
Poll respondents appreciate economic benefits of innovation and call for more protections
Foreign government price setting by any name harms innovation and access to medicines
Compulsory licensing: A misused and abused international trade law
Government-imposed price controls threaten innovation and access
ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation
Illegal trade barriers discriminate against U.S. innovators
Trading fair means upholding the law: A focus on patents
Enforcing unmet trade obligations protects U.S. innovation
NAFTA tribunal fails to rule on Canada’s patent utility doctrine
PhRMA urges USTR to protect American innovators abroad
"As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority"
Trade
As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority
"As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority"